The FOXO4-DRI peptide is designed to mimic a portion of the FOXO4 protein, but with a key difference: it competes with the natural FOXO4 protein for binding to the p53 protein
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show substantial efficacy in regulating blood glucose levels and lipid metabolism, initially as an effective treatment for diabetes mellitus
Adults received either placebo or EMP+ (Vit A 5760IU, Vit C 600 mg, Vit D 1440 IU, Vit E 360 IU, B1 18 mg, B2 13.5 mg, B3 90 mg,B5 21.6 mg, B6 36 mg, B9 1440 g, B12 900 g, Biotin 1080 g, Pantothenic acid21.6 mg, Ca 1320 mg, Fe 13.74 mg, P 840mg, I 204 g, Mg 600 mg, Zn 48 mg, Se204 g, Cu 7.2 mg, Mn 9.6 mg, Cr 624 g, Mo 144 g, K 240 mg, Germaniumsesquioxide 20.7 mg, B 2400 g, V 1194 g, Ni 29.4 g, Choline bitartrate 540mg, DL-phenylalanine 360 mg, Citrus bioflavonoids 240 mg, Inositol 180 mg,Glutamine 180 mg, L-methionine 60 mg, Gingko biloba 36 mg, grape seed extract45 mg)
PLoS One (2015) 10(7):e0132744.10.1371/journal.pone.0132744 30 PereiraMJeyabalanJJorgensenCSHopkinsonMAl-JazzarARouxJPet alChronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice
Not recommended for children and pregnant women (caffeine content: 125 mg/ portion = 1 ampoule)